# Erector Spinae Plane Block Versus Trigger Point Injection for Chronic Thoracic Myofascial Pain

> **NCT07632820** · PHASE4 · RECRUITING · sponsor: **Mayo Clinic** · enrollment: 76 (estimated)

## Conditions studied

- Back Pain

## Interventions

- **DRUG:** Erector Spinae Plane (ESP) Block with 0.5% Plain Bupivacaine
- **DRUG:** Trigger Point Injection (TPI) with 0.5% Plain Bupivacaine

## Key facts

- **NCT ID:** NCT07632820
- **Lead sponsor:** Mayo Clinic
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-08-13
- **Primary completion:** 2029-08-01
- **Final completion:** 2029-08-30
- **Target enrollment:** 76 (ESTIMATED)
- **Last updated:** 2026-09-09

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07632820

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07632820, "Erector Spinae Plane Block Versus Trigger Point Injection for Chronic Thoracic Myofascial Pain". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07632820. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*